Tristel PLC

LSE TSTL.L

Tristel PLC Price to Sales Ratio (P/S) on January 14, 2025: 4.48

Tristel PLC Price to Sales Ratio (P/S) is 4.48 on January 14, 2025, a -27.87% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Tristel PLC 52-week high Price to Sales Ratio (P/S) is 7.07 on February 02, 2024, which is 57.93% above the current Price to Sales Ratio (P/S).
Tristel PLC 52-week low Price to Sales Ratio (P/S) is 3.50 on December 20, 2024, which is -21.71% below the current Price to Sales Ratio (P/S).
Tristel PLC average Price to Sales Ratio (P/S) for the last 52 weeks is 5.93.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

LSE: TSTL.L

Tristel PLC

CEO	Mr. Matthew G. Sassone
IPO Date	June 1, 2005
Location	United Kingdom
Headquarters	Lynx Business Park
Employees	250
Sector	Health Care
Industries Pharmaceuticals

Description

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.

Key trends

Past 5 years